Consequently, inhibiting RAS activation, NLRP3, and TGF-β1 expression could offer novel therapeutic avenues for managing asthma in patients with both obesity and asthma. This evidence concerns the gene NLRP3 and obesity due to melanocortin 4 receptor deficiency.